AC Immune Results and Corporate Update

 

• ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2
• ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2
• ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designation
• ACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partner
• Cash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026

https://www.globenewswire.com/news-release/2024/03/14/2846139/0/en/AC-Immune-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html